Navigation Links
John Theurer Cancer Center first in New Jersey to offer complete capabilities of Provenge

HACKENSACK, N.J. (April 4, 2011) The John Theurer Cancer Center at Hackensack University Medical is the only cancer center in New Jersey where advanced prostate cancer patients can receive a cell collection process and infusion of Provenge (Sipuleucel-T). Now, patients can find the complete capabilities of this breakthrough immunotherapy in one center led by one physician.

"We are now able to provide patients with care that is not only innovative for improved outcomes, but convenient and more personal," said Robert Alter, M.D., Co-Chief, Urologic Oncology at the John Theurer Cancer Center. "Throughout the Provenge delivery process, patients are treated by a single team of our expert staff, allowing for a more intimate, comforting course of treatment."

Provenge is the first autologous cellular immunotherapy available for the treatment of advanced prostate cancer, meaning it is designed to use cells from a patient's own immune system to identify and target prostate cancer. The John Theurer Cancer Center participated in the Provenge clinical trials, and began prescribing and infusing patients when the treatment was approved in June 2010. This February, the John Theurer Cancer Center received approval by Provenge manufacturer, Dendreon, to conduct leukapheresis, a cell collection process vital for the development of the immunotherapy.

"Provenge is another example of the cutting-edge treatments we provide our patients at the John Theurer Cancer Center," said Andrew L. Pecora, M.D., F.A.C.P., C.P.E., Chief Innovations Officer and Professor and Vice President of Cancer Services at the John Theurer Cancer Center. "We strive to deliver patients with the latest treatment options and state-of-the-art technology in order to deliver exceptional care."

Provenge treatment at the John Theurer Cancer Center begins with leukapheresis, a cell collection process administered by a clinical assistant. The patient's cells are sent to a Provenge manufacturing facility, where they are combined with a protein that is found in most prostate cancers linked to an immune stimulating agent. The dose of Provenge is then sent back to the cancer center for infusion. This whole process is performed three times over approximately six weeks for complete treatment.


Contact: Jaymie DeGaetano
John Theurer Cancer Center

Related medicine news :

1. The MMRF and John Theurer Cancer Center to host patient symposium
2. John Theurer Cancer Center orthopedic oncologist shares new limb sparing surgical techniques
3. John Theurer Cancer Center to host Eighth Annual Northern New Jersey Breast Cancer Conference
4. Oncology basic research director at John Theurer Cancer Center continues transplantation research
5. John Theurer Cancer Center presents studies on promising therapies for aggressive blood cancers
6. The John Theurer Cancer Center to unveil 40 presentations at the 52nd ASH Annual Meeting
7. John Theurer Cancer Center to present innovative research at 2 surgical meetings
8. John Theurer Cancer Center first cancer center in N.J. to acquire new radiotherapy system
9. John Theurer Cancer Center and LLS host panel discussion with leading hematologists
10. The John Theurer Cancer Center recognizes medical physics team for safety track record
11. John Theurer Cancer Center experts present new cancer research at ASCO Annual Meeting
Post Your Comments:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... for mental health professionals, announced today its affiliation with Tennessee Counseling Association. ... solutions to the network of the Tennessee Counseling Association, adding exclusive benefits and ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American Institutes ... Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , ... advance care planning, healthcare costs and patient and family engagement. , AIR researchers ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced ... feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as a ... has released tools for healthy coping following a traumatic event. , Trauma sufferers tend ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... Story Highlights: ... the health care industry is causing providers to review ... Deloitte offers a suite of solutions for health care ... cost optimization: labor resource analysis, revenue cycle optimization and ... outcomes and better economics ...
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
(Date:6/24/2016)... 24, 2016 Research and ... "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" report ... In-Mold Electronics, Smart Skin, Structural Health Monitoring, ... Structural electronics involves electronic and/or electrical components ... replacing dumb structures such as vehicle bodies or ...
Breaking Medicine Technology: